NOVONIX (NVX) CFO reports sizable performance rights in Form 3 filing

Rhea-AI Filing Summary

NOVONIX Ltd’s Chief Financial Officer Robert Buell Long filed an initial ownership report showing his equity-based incentives. The Form 3 lists performance rights that can convert into 1,363,398 ordinary shares expiring in 2028, 2,069,142 shares expiring in 2029, and 1,144,130 shares expiring in 2027, all with a conversion price of $0.0000.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Long Robert Buell

(Last) (First) (Middle)

1029 WEST 19TH STREET

(Street)

CHATTANOOGA TN 37408

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2026

3. Issuer Name and Ticker or Trading Symbol
NOVONIX Ltd [ NVX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance rights	12/31/2027	12/31/2028	Ordinary shares	1,363,398	$0	D
Performance rights	12/31/2028	12/31/2029	Ordinary shares	2,069,142	$0	D
Performance rights	12/31/2026	12/31/2027	Ordinary shares	1,144,130	$0	D

Explanation of Responses:

Remarks:

Performance rights vest based on 3 year TSR performance subject to a revenue modifier.

	Suzanne Yeates	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the NOVONIX (NVX) Form 3 filing show for the CFO?

The Form 3 shows NOVONIX’s CFO Robert Buell Long reporting existing performance rights, not new market trades. These rights can convert into ordinary shares over several years, outlining his current equity-based incentive position with the company.

How many NOVONIX ordinary shares underlie the CFO’s performance rights?

The CFO’s disclosed performance rights relate to three blocks of underlying ordinary shares: 1,363,398, 2,069,142, and 1,144,130 shares. Together they show a substantial equity-based interest tied to future company performance and vesting conditions.

What are the expiration dates of NOVONIX CFO Robert Long’s performance rights?

The performance rights disclosed expire on three different dates: in 2027, 2028, and 2029. These staggered expirations illustrate a long-term incentive structure designed to keep the CFO’s interests aligned with NOVONIX’s multi‑year performance.

What is the exercise price of the NOVONIX CFO’s performance rights?

The performance rights reported by NOVONIX’s CFO have an exercise or conversion price of $0.0000 per share. This structure effectively makes them costless to exercise once the vesting and performance conditions are satisfied, emphasizing performance rather than purchase cost.

Does the NOVONIX Form 3 indicate insider buying or selling of NVX shares?

The Form 3 does not indicate insider buying or selling of NOVONIX shares. It is an initial ownership statement listing existing performance rights and their underlying ordinary shares, rather than recording open-market purchases or sales.